Status:

COMPLETED

TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery

Lead Sponsor:

University Hospital, Bordeaux

Collaborating Sponsors:

Ministry of Health, France

Conditions:

Postpartum Hemorrhage

Eligibility:

FEMALE

18-64 years

Phase:

PHASE3

Brief Summary

The aim is to assess the impact of tranexamic acid (TXA) for preventing postpartum hemorrhage (PPH) following a cesarean section (CS).

Detailed Description

Regarding the prevention of PPH, recent randomized controlled trials (RCTs) of unclear quality have suggested that TXA may reduce blood loss and maternal morbidity, while a Cochrane Collaboration revi...

Eligibility Criteria

Inclusion

  • : adult women admitted for a cesarean delivery before or during labor, at a term ≥ 34 weeks,
  • hemoglobin level at the last blood sample \>9g/dl,
  • available blood test for Hb and Ht within one week before caesarean delivery,
  • informed signed consent

Exclusion

  • previous thrombotic event or preexisting pro-thrombotic disease,
  • epileptic state or history of seizures,
  • presence of any chronic or active cardiovascular disease outside hypertension,
  • any chronic or active renal disease and chronic or active liver disease at risk thrombotic or hemorrhagic, autoimmune disease,
  • sickle cell disease,
  • placenta praevia,
  • placenta accreta/increta/percreta,
  • abruption placentae,
  • eclampsia,
  • HELLP syndrome,
  • significant hemorrhage before cesarean section
  • in utero fetal death,
  • administration of low-molecular-weight heparin or antiplatelet agents during the week before delivery,
  • planned general anesthesia,
  • hypersensitivity to tranexamic acid or concentrated hydrochloric acid,
  • instrumental extraction failure,
  • multiple pregnancy with vaginal delivery of the first child,
  • poor understanding of the French language.

Key Trial Info

Start Date :

March 3 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 8 2020

Estimated Enrollment :

4574 Patients enrolled

Trial Details

Trial ID

NCT03431805

Start Date

March 3 2018

End Date

April 8 2020

Last Update

April 29 2020

Active Locations (26)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (26 locations)

1

CHU Angers

Angers, France, 49033

2

CHU Jean Minjoz

Besançon, France, 25000

3

CHU Bordeaux

Bordeaux, France, 33076

4

CHRU Côte de Nacre

Caen, France, 14033